Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6421
    -0.0004 (-0.07%)
     

  • OIL

    83.34
    +0.61 (+0.74%)
     

  • GOLD

    2,405.20
    +7.20 (+0.30%)
     

  • Bitcoin AUD

    99,549.05
    +599.72 (+0.61%)
     

  • CMC Crypto 200

    1,375.52
    +62.90 (+4.79%)
     

  • AUD/EUR

    0.6019
    -0.0012 (-0.20%)
     

  • AUD/NZD

    1.0898
    +0.0023 (+0.21%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,037.65
    -356.67 (-2.05%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,986.40
    +211.02 (+0.56%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors to Contact Firm’s Attorneys Now, Securities Fraud Case Filed

Hagens Berman Sobol Shapiro LLP
·2-min read

SAN FRANCISCO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.

Class Period: Feb. 2, 2021 – Aug. 24, 2021
Lead Plaintiff Deadline: Oct. 26, 2021
Visit: www.hbsslaw.com/investor-fraud/SAVA
Contact An Attorney Now: SAVA@hbsslaw.com | 844-916-0895

Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action:

The complaint alleges that Cassava and senior management made false and misleading statements and failed to disclose that the quality and integrity of the scientific data supporting the company’s claims of efficacy for its Alzheimer’s drug (simufilam) were overstated and biased.

ADVERTISEMENT

Specifically, Defendants falsely (1) claimed that results from an interim analysis of simufilam demonstrated that patients’ cognition and behavior scores both improved following six months of simufilam treatment, and (2) touted an FDA meeting they stated supported green-lighting a Phase 3 trial beginning in the second half of 2021

The truth emerged on Aug. 24, 2021, when reports surfaced that a citizen petition was submitted to the FDA asking the FDA to halt all ongoing studies with simufilam while the agency verifies data the company has submitted so far. The petition raises serious concerns about the quality and integrity of the laboratory-based studies surrounding this drug candidate. The petition further identified “errors and anomalies” in the data “of a sufficient frequency and magnitude to strongly suggest scientific misconduct.”

On this news, the price of Cassava common stock plummeted, declining $37 per share, or 32%, on unusually high trading volume.

“We’re focused on investors’ losses and proving Cassava manipulated clinical data for simufilam,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Cassava and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Cassava should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email SAVA@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 844-916-0895